170 7 9 27 10 6 143 7 6 continues (STATA Corporation)
STATA Corporation is a verified supplier 
99
Structured Review
STATA Corporation
170 7 9 27 10 6 143 7 6 continues
170 7 9 27 10 6 143 7 6 Continues, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 18837 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/170+7+9+27+10+6+143+7+6+continues/STATA+10%2E0/pm33501722-57-360-367
Average 99 stars, based on 18837 article reviews
170 7 9 27 10 6 143 7 6 Continues, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 18837 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/170+7+9+27+10+6+143+7+6+continues/STATA+10%2E0/pm33501722-57-360-367
Average 99 stars, based on 18837 article reviews
170 7 9 27 10 6 143 7 6 continues - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
Control:Article Title: Novel bleeding risk score for patients with atrial fibrillation on oral anticoagulants, including direct oral anticoagulants. Article Snippet: .. TA B L E 1 Baseline characteristics All (n = 2147) Major & relevant bleeding (n = 255) No bleeding (n = 1892) Age (years)a 73.4 ± 8.2 73.1 ± 8.3 75.9 ± 8.2 Sex (%) Male 1556 (72.5) 1367 (72.3) 189 (74.12) Female 591 (27.5) 525 (27.7) 66 (27.53) Height (cm) 172.2 ± 9.0 172.1 ± 8.6 172.2 ± 9.0 Weight (kg) 82.6 ± 16.4 82.6 ± 16.4 82.6 ± 15.9 Type of AF (%)b Paroxysmal 919 (42.8) 106 (41.6) 813 (43.0) Persistent 652 (30.4) 70 (27.5) 582 (30.8) Permanent 576 (26.8) 79 (31.0) 497 (26.2) Smoking (%)c Active 145 (6.8%) 15 (5.88) 130 (6.88) Former smoker 1062 (49.5) 118 (46.27) 944 (49.97) Never smoker 937 (43.6%) 122 (47.84) 815 (43.14) Type of VKA (%)d 938 (43.7) 126 812 Phenprocoumon 725 (33.8) 113 (44.3) 612 (32.4) Acenocoumarol 213 (9.9) 13 (5.1) 200 (10.6) DOAC (%)d 1209 (56.3) 129 (50.6) 1080 (57.1) Rivaroxaban 886 (41.3) 88 (34.5) 798 (42.2) Dabigatran 79 (3.7) 11 (4.3) 68 (3.6) Apixaban 204 (9.5) 27 (10.6) 177 (9.4) Edoxaban 40 (1.9) 3 (1.2) 37 (2.0) Poor INR control (%)e 89 (4.15) 13 (5.1) 76 (4.0) Prior stroke/TIA (%)f 443 (20.6) 67 (26.3) 376 (19.9) Heart failure (%) 569 (26.5) 83 (32.6) 486 (25.7) Hypertension (%)g 1516 (70.6) 209 (82.0) 1307 (69.1) Hemoglobin (g/L)h 135.5 ± 19.1 131.6 ± 19.4 136.1 ± 19.0 Hematocrit (L/L)h 40.4 ± 5.4 39.6 ± 5.4 40.6 ± 5.4 Thrombocytes (G/L)h 223.4 ± 73.2 216.1 ± 71.4 224.4 ± 73.4 History of cancer (%)i 339 (15.8) 54 (21.2) 285 (15.1) Prior major haemorrhage (%) 48 (2.24) 10 (3.9) 38 (2.0) Diabetes (%) 373 (17.4) 38 (14.9) 335 (17.7) History of falls (%) 179 (8.3) 29 (11.4) 150 (7.9) Prior gastric ulcer (%) 93 (4.3) 17 (6.7) 76 (4.0) Coronary artery disease (%) 351 (16.4) 46 (18.0) 305 (16.1) Other embolic events (%) 112 (5,2) 16 (6.3) 96 (5.1) History of VTE (%) 205 (0.6) 23 (9.0) 182 (9.6) Antiplatelet therapy (%) 340 (15.8) 46 (18.0) 294 (15.6) Use of NSAID (%) 47 (2.2) 8 (3.1) 39 (2.1) Use of PPI (%)j 664 (30.9) 97 (38.0) 567 (30.0) Peripheral arterial disease (%) Protein-Protein interactions:Article Title: Novel bleeding risk score for patients with atrial fibrillation on oral anticoagulants, including direct oral anticoagulants. Article Snippet: .. TA B L E 1 Baseline characteristics All (n = 2147) Major & relevant bleeding (n = 255) No bleeding (n = 1892) Age (years)a 73.4 ± 8.2 73.1 ± 8.3 75.9 ± 8.2 Sex (%) Male 1556 (72.5) 1367 (72.3) 189 (74.12) Female 591 (27.5) 525 (27.7) 66 (27.53) Height (cm) 172.2 ± 9.0 172.1 ± 8.6 172.2 ± 9.0 Weight (kg) 82.6 ± 16.4 82.6 ± 16.4 82.6 ± 15.9 Type of AF (%)b Paroxysmal 919 (42.8) 106 (41.6) 813 (43.0) Persistent 652 (30.4) 70 (27.5) 582 (30.8) Permanent 576 (26.8) 79 (31.0) 497 (26.2) Smoking (%)c Active 145 (6.8%) 15 (5.88) 130 (6.88) Former smoker 1062 (49.5) 118 (46.27) 944 (49.97) Never smoker 937 (43.6%) 122 (47.84) 815 (43.14) Type of VKA (%)d 938 (43.7) 126 812 Phenprocoumon 725 (33.8) 113 (44.3) 612 (32.4) Acenocoumarol 213 (9.9) 13 (5.1) 200 (10.6) DOAC (%)d 1209 (56.3) 129 (50.6) 1080 (57.1) Rivaroxaban 886 (41.3) 88 (34.5) 798 (42.2) Dabigatran 79 (3.7) 11 (4.3) 68 (3.6) Apixaban 204 (9.5) 27 (10.6) 177 (9.4) Edoxaban 40 (1.9) 3 (1.2) 37 (2.0) Poor INR control (%)e 89 (4.15) 13 (5.1) 76 (4.0) Prior stroke/TIA (%)f 443 (20.6) 67 (26.3) 376 (19.9) Heart failure (%) 569 (26.5) 83 (32.6) 486 (25.7) Hypertension (%)g 1516 (70.6) 209 (82.0) 1307 (69.1) Hemoglobin (g/L)h 135.5 ± 19.1 131.6 ± 19.4 136.1 ± 19.0 Hematocrit (L/L)h 40.4 ± 5.4 39.6 ± 5.4 40.6 ± 5.4 Thrombocytes (G/L)h 223.4 ± 73.2 216.1 ± 71.4 224.4 ± 73.4 History of cancer (%)i 339 (15.8) 54 (21.2) 285 (15.1) Prior major haemorrhage (%) 48 (2.24) 10 (3.9) 38 (2.0) Diabetes (%) 373 (17.4) 38 (14.9) 335 (17.7) History of falls (%) 179 (8.3) 29 (11.4) 150 (7.9) Prior gastric ulcer (%) 93 (4.3) 17 (6.7) 76 (4.0) Coronary artery disease (%) 351 (16.4) 46 (18.0) 305 (16.1) Other embolic events (%) 112 (5,2) 16 (6.3) 96 (5.1) History of VTE (%) 205 (0.6) 23 (9.0) 182 (9.6) Antiplatelet therapy (%) 340 (15.8) 46 (18.0) 294 (15.6) Use of NSAID (%) 47 (2.2) 8 (3.1) 39 (2.1) Use of PPI (%)j 664 (30.9) 97 (38.0) 567 (30.0) Peripheral arterial disease (%) |